Clinical Trials and Studies
Some clinical trials have suspended enrollment until further notice due to COVID-19 considerations.
Blood Disorders and Hematologic Cancers
- AB-101 with or without Rituximab for Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
- Acute Myeloid Leukemia: Venetoclax and Azacitidine Study
- Assessing the Anti-Tumor Activity and Safety of REGN1979 in Patients with Relapsed or Refractory Follicular Lymphoma
- Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients (VICD)
- CGT9486 Treatment for Advanced Systemic Mastocytosis
- Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease Treatment Study
- Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria
- Diffuse Large B-Cell Lymphoma of the Activated B-Cell Subtype Treatment Study
- Drug Treatment Study for Children with Hemophilia A
- Drug Treatment Study for High Grade B-Cell Lymphomas
- Drug Treatment Study for Patients with Follicular Lymphoma
- Evaluation of Pediatric Palliative Inpatient Process
- FLT3 Mutated Acute Myeloid Leukemia Treatment Study
- Health Literacy and Numeracy in Adolescent Patients with Hemophilia A and B Study
- Hemophilia A or B Treatment Study
- Hemophilia A Treatment Study
- Hodgkin Lymphoma and CD30-Expressing Peripheral T-cell Lymphoma Treatment Study
- Luspatercept Versus Placebo for Treating Subjects with Myelofibrosis on JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions
- Luspatercept versus Placebo in Subjects with Myeloproliferative Neoplasm-Associated Myelofibrosis
- Mantle Cell Lymphoma Treatment Study
- Mapping of CD34+ Cells From Healthy Participants and Patients with Myelofibrosis and Polycythemia Vera
- Molecular and Clinical Biology of von Willebrand Disease Study
- Mosunetuzumab Treatment for DLBCL After First-Line Immunochemotherapy, Alone, or in Combination with Polatuzumab Vedotin for Previously Untreated DLBCL
- Myelofibrosis: Phase 3 Study of Navitoclax Plus Ruxolitinib Versus Ruxolitinib
- National Registry of All Persons with Bleeding and Clotting Disorders
- Newly Diagnosed T-Lymphoblastic Leukemia and T-Lymphoblastic Lymphoma Treatment Study
- Nivolumab and Combination Chemotherapy in Treating Participants with Diffuse Large B-Cell Lymphoma
- Public Health Surveillance for the Prevention of Complications of Bleeding and Clotting Disorders
- Relapsed or Refractory Follicular Lymphoma Treatment Study
- Specimen Collection from ALL or CML Patients for the Xpert BCR-ABL Ultra p190 Test
- Specimen Collection from ALL or CML Patients with a Detectable BCR-ABL p190 Fusion Transcript Level
- Study for Patients with Acute Myelogenous Leukemia
- Study for Patients with Acute Myeloid Leukemia
- Study for Patients with Non-Advanced Systemic Mastocytosis
- Study for Patients with Primary Immune Thrombocytopenia
- Study for Patients with Relapsed/Refractory (R/R) FLT3+ Acute Myeloid Leukemia (AML)
- Study of Biomarkers in Hemophilic Arthropathy
- Study of Hepatitis C Virus Outcomes After Treatment in Patients with Bleeding Disorders
- Study of Uproleselan Administered with Chemotherapy in Patients with Relapsed/Refractory Acute Myeloid Leukemia
- Study Treating Patients With High-Risk Smoldering Myeloma
- Tafasitamab + Lenalidomide + R-CHOP versus R-CHOP to Treat Diffuse Large B-Cell Lymphoma
- Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia
- The National Myelodysplastic Syndromes Study
- Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Study
- Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Study
- Treatment Study for Children with Hemophilia B
- Treatment Study for Newly Diagnosed High Risk B-Lymphoblastic Leukemia in Patients with Ph-like TKI Sensitive Mutations
- Treatment Study for Older Patients with Acute Lymphoblastic Leukemia
- Treatment Study for Patients with Diffuse Large B-Cell Lymphoma After aHCT
- Treatment Study for Patients with Localized Central Nervous System Germ Cell Tumors
- Treatment Study for Patients with Newly Diagnosed B-Lymphoblastic Leukemia or B-Lineage Lymphoblastic Lymphoma
- Treatment Study for Patients with Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
- Treatment Study for Patients with Rare Tumors
- Treatment Study for Patients with Untreated Mantle Cell Lymphoma
- Treatment Study for Pediatric Patients with Hemophilia A
- Treatment Study for Subjects with Myelofibrosis Who Have Failed a JAK Inhibitor
- Treatment Study for Subjects with Severe Hemophilia A or B
- Treatment Study for Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
- Venetoclax with Azacitidine for Newly Diagnosed Myelodysplastic Syndrome
- Zandelisib Treatment for Follicular or Marginal Zone Lymphoma After Failure of 2 or More Prior Therapies